CD BioGlyco

The invention of medical Oligonucleotides made medical treatment for genetic disorders revolutionary. On April 12, 2024, S. L. Lovelock's team from the University of Manchester published an article entitled "Modern approaches to therapeutic oligonucleotide manufacturing". The paper elaborates the way to optimize the efficiency of production, consistent products, large scale production to serve the market with […]

In recent years, the research and development and clinical treatment of small nucleic acid drugs have achieved many breakthrough results. It has become a new global investment outlet and a must-win for biopharmaceutical giants, and nucleic acid therapy has entered the fast lane. Drugs made of small nucleic acids target mRNA in cells mostly through the […]

The growing demand for nucleic acid drugs and vaccines highlights the urgent need for improved technologies to produce long DNA and RNA sequences with Chemical Modifications. Unlike DNA, surprisingly little effort has been devoted to making therapeutic RNA Oligonucleotides longer than the short sequences (20-80 nt) used for small interfering RNA (siRNA) and microRNA (miRNA). In […]

In January 2024, Kohji Yamada and Akira Mine published an article titled "Sugar coordinates plant defense signaling" in Science Advances, revealing the crucial role of Sugar in coordinating the defense system of the model plant Arabidopsis thaliana, and drawing a signaling flowchart of sugar in plant defense. Plants have formed a variety of constitutive and inducible defense […]

The development of nucleic acid therapy requires efficient chemical reactions to connect oligonucleotides with functional chemical modules to improve their stability, promote cellular uptake and achieve specific targeting. In the currently used siRNA therapy, the 3' end of the oligonucleotide is mainly modified with triple-N-acetylgalactosamine (GalNAc)3. However, the implementation of this modification method requires cumbersome […]

Since the first ADC drug Mylotarg (gemtuzumab ozogamicin) was approved by the FDA in 2000, a total of 15 ADC drugs have been approved for marketing worldwide to treat hematological malignancies and solid tumors. In addition, more than 400 ADC drugs are in different stages of development. Of the 15 approved ADC drugs, 13 are […]

As the basic components of RNA and DNA, purine nucleotides play an important role in cellular material metabolism and energy metabolism. For this reason, cells need an adequate supply of purine nucleotides to meet the needs of growth and proliferation. However, we still do not know how normal or malignant tumor tissues maintain nucleotide metabolic […]

Background With the application of nucleic acids in the treatment of diseases, human attention to nucleic acids in medicine is gradually increasing. In order to obtain a large amount of nucleic acids in a short time for use in the pharmaceutical field, the in vitro synthesis of nucleic acids is particularly important. The in vitro Synthesis of nucleic […]